Look out, Regeneron. As the threat from Roche's Vabysmo grows, one team of analysts slashes its Eylea sales estimate

Submitted by admin on July 25, 2022 - 10:00pm

Source:

Fierce Pharma

News Tags:

Regeneron

Eylea

Roche

Vabysmo

Headline:

Look out, Regeneron. As the threat from Roche's Vabysmo grows, one team of analysts slashes its Eylea sales estimate

snippet:

Regeneron's Eylea has long dominated the ophthalmology market thanks to its strong efficacy and safety profile. But its unquestioned run at the top now appears under threat.

Search form

You are here

Look out, Regeneron. As the threat from Roche's Vabysmo grows, one team of analysts slashes its Eylea sales estimate

Look out, Regeneron. As the threat from Roche's Vabysmo grows, one team of analysts slashes its Eylea sales estimate